Pharma Pulse 9/5/24: FDA Wants Safer Cancer Drugs, Can Outcomes-Based Agreements Work for Weight Loss Drugs? & more

Take Control of Site Costs with Clinical Research Terminology Codes

While measuring and managing site costs can be challenging, these codes can aid in accounting for labor expenses, budgeting for sponsors, and more.

Can Outcomes-Based Agreements Work for Weight Loss Drugs?

Outcomes-based agreements can take away clinical uncertainties, so payers have a guarantee that they're not spending money on something that’s not going to work.

FDA Wants Safer Cancer Drugs, but Some Startups Fear Unintended Consequences

Companies developing cancer drugs wrestle with ‘Project Optimus’

Viz.ai and ALCMI Partner to Unite AI and Lung Cancer Research Communities

Viz.ai announced a partnership with the Addario Lung Cancer Medical Institute (ALCMI), an international consortium made up of 25 of the world’s premier lung cancer research institutions. Together, Viz.ai and ALCMI will collaborate on improving lung cancer outcomes in patients by focusing on early detection with improved clinical workflow for nodule workup through to precision medicine optimization.

Ilisa Bernstein on LinkedIn

Thanks Nico for this sit down previewing a few of the key and timely legal and regularly aspects of DSCSA that were discussed at the HDA - Healthcare Distribution Alliance Traceability Seminar last week. The clock is ticking for drug supply chain compliance with DSCSA!

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs